Subscribe
heidi-besen
Heidi Besen / Shutterstock.com
5 June 2020Big PharmaRory O'Neill

Has the public got the taste for free medicine?

The COVID-19 pandemic has seen the fundamental principles of the IP system, normally a touchstone of advanced economies, called into question. Governments and manufacturers alike are under pressure to assure the public that IP will not be a barrier to accessing the tools needed to fight the disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.

More on this story

Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims